BRPI0516776A - muteìnas antagonistas quiméricas de interleucina-9 e interleucina-4 e métodos de uso das mesmas - Google Patents

muteìnas antagonistas quiméricas de interleucina-9 e interleucina-4 e métodos de uso das mesmas

Info

Publication number
BRPI0516776A
BRPI0516776A BRPI0516776-0A BRPI0516776A BRPI0516776A BR PI0516776 A BRPI0516776 A BR PI0516776A BR PI0516776 A BRPI0516776 A BR PI0516776A BR PI0516776 A BRPI0516776 A BR PI0516776A
Authority
BR
Brazil
Prior art keywords
interleukin
methods
antagonists
chimeric
mutein
Prior art date
Application number
BRPI0516776-0A
Other languages
English (en)
Inventor
David C Boisvert
Malinda Longphre
Teresa M Wong
Sydney M Zaremba
Original Assignee
Aerovance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerovance Inc filed Critical Aerovance Inc
Publication of BRPI0516776A publication Critical patent/BRPI0516776A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MUTEìNAS ANTAGONISTAS QUIMéRICAS DE INTERLEUCINA-9 E INTERLEUCINA-4 E MéTODOS DE USO DAS MESMAS. A presente invenção refere-se a antagonistas quiméricos de polipeptídeo que incluem uma muteína de interleucina-4 (IL-4) ligada a uma muteína de interleucina-9 (IL-9), como são polinucleotídeos que codificam os antagonistas de muteína quiméricos de IL-4 e IL-9. Também são fornecidos métodos de usar os antagonistas de muteína quiméricos e codificar polipeptídeo para reduzir ou inibir a responsividade de uma célula a uma citocina tal como IL-4, IL-9 e/ou interleucina-13. Métodos usando as composições para tratar desordens tais como desordens pulmonares (por exemplo asma) também são fornecidos.
BRPI0516776-0A 2004-09-22 2005-09-21 muteìnas antagonistas quiméricas de interleucina-9 e interleucina-4 e métodos de uso das mesmas BRPI0516776A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61227504P 2004-09-22 2004-09-22
US11/026,396 US7635754B2 (en) 2004-09-22 2004-12-29 Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
PCT/US2005/034388 WO2006036878A2 (en) 2004-09-22 2005-09-21 Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same

Publications (1)

Publication Number Publication Date
BRPI0516776A true BRPI0516776A (pt) 2008-09-23

Family

ID=36074534

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516776-0A BRPI0516776A (pt) 2004-09-22 2005-09-21 muteìnas antagonistas quiméricas de interleucina-9 e interleucina-4 e métodos de uso das mesmas

Country Status (12)

Country Link
US (2) US7635754B2 (pt)
EP (1) EP1805198A4 (pt)
JP (1) JP2008513518A (pt)
KR (1) KR20070068396A (pt)
AU (1) AU2005289639A1 (pt)
BR (1) BRPI0516776A (pt)
CA (1) CA2581469A1 (pt)
IL (1) IL181898A (pt)
NO (1) NO20071591L (pt)
NZ (1) NZ553897A (pt)
RU (1) RU2007114958A (pt)
WO (1) WO2006036878A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121792A2 (en) 2005-05-05 2006-11-16 Archipelago Holdings, Inc. Unpriced order auction and routing
US7873561B1 (en) 2005-05-05 2011-01-18 Archipelago Holdings, Inc. Method and system for maintaining an order on a selected market center with maximum price exemption parameter
AU2006244562B2 (en) 2005-05-05 2012-05-17 Nyse Group, Inc. Reprice-to-block order
WO2006121796A2 (en) 2005-05-05 2006-11-16 Archipelago Holdings, Inc. Tracking liquidity order
US7912775B1 (en) 2005-05-05 2011-03-22 Archipelago Holdings, Inc. Liquidity analysis system and method
JP2009525267A (ja) * 2006-01-11 2009-07-09 アエロヴァンス インコーポレイティッド ヒトおよび非ヒト霊長類において喘息を処置するための方法および組成物
WO2009009775A1 (en) * 2007-07-11 2009-01-15 Aerovance, Inc. Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
EP3448413A1 (en) * 2016-04-26 2019-03-06 Five Prime Therapeutics, Inc. Treating respiratory diseases by targeting interleukin 4 induced 1 (il4i1)
KR20190133707A (ko) * 2017-03-31 2019-12-03 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 신테카인 조성물 및 사용방법
EP3530320B1 (en) * 2018-02-27 2023-11-15 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Novel il-4-/il-13-derived peptide compounds for the treatment or prevention of neurodegenerative or neuroinflammatory diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5314695A (en) * 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
WO1997008321A1 (en) * 1995-08-24 1997-03-06 Magainin Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
EP0918858A1 (en) * 1996-05-10 1999-06-02 Biogen, Inc. Common gamma chain blocking agents
US5827533A (en) * 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
WO2004103295A2 (en) 2003-05-14 2004-12-02 Bayer Pharmaceuticals Corporation Interleukin-9 antagonist muteins and their pharmacological methods of use

Also Published As

Publication number Publication date
IL181898A0 (en) 2007-07-04
EP1805198A4 (en) 2010-01-20
EP1805198A2 (en) 2007-07-11
KR20070068396A (ko) 2007-06-29
AU2005289639A1 (en) 2006-04-06
JP2008513518A (ja) 2008-05-01
RU2007114958A (ru) 2008-10-27
CA2581469A1 (en) 2006-04-06
NZ553897A (en) 2011-01-28
US20060063236A1 (en) 2006-03-23
IL181898A (en) 2011-04-28
WO2006036878A3 (en) 2009-04-09
US20100099618A1 (en) 2010-04-22
US7635754B2 (en) 2009-12-22
NO20071591L (no) 2007-06-21
WO2006036878A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
BRPI0516776A (pt) muteìnas antagonistas quiméricas de interleucina-9 e interleucina-4 e métodos de uso das mesmas
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
HK1084404A1 (en) Muteins of tear lipocalin
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
DE602006018969D1 (de) Herstellung und reinigung von il-29
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
CL2004002050A1 (es) Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
WO2008060813A3 (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
NO20063171L (no) Endoparasitisidale sammensetninger for topisk anvendelse
EP2592072A3 (en) Human protein tyrosine phosphatase inhibitors and their use
BRPI0417072A (pt) agente preventivo para a vasculite
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
TW200505875A (en) Novel compounds
NO20065536L (no) Behandling av astma hos barn
UY29440A1 (es) Nuevos compuestos
TW200407425A (en) Human coagulation factor VII polypeptides
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
CL2003002678A1 (es) Compuestos derivados de piperidina, moduladores de la actividad del receptor ccr5; procedimiento de preparacion; composicion farmaceutica, y su uso en el tratamiento de enfermedades inmunologicas, inflamatorias, asma, artritis reumatoidea y ateroescl
AU2003223124A1 (en) Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same
AU2002304249A1 (en) Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
CL2003002722A1 (es) Compuestos derivados de 1-piperidin-3-il-4-piperidin-4-il-piperazina sustituida; composicion farmaceutica; procedimiento de preparacion de intermediarios; y el uso para tratar esquizofrenia, ansiedad, depresion, asma, desordenes de la micturacion, do
CY1111319T1 (el) Ενωση 4-μεθυλεξανοϊκης κααλαλιδης f

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]